On November 30, 2019 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, reported its participation at the 2018 Citi Global Healthcare Conference (Press release, Calithera Biosciences, NOV 30, 2018, View Source [SID1234535232]). Calithera will host meetings with investors at the conference in New York on Thursday, December 6, 2018.
On November 30, 2018 TG Therapeutics, Inc. (NASDAQ: TGTX), reported that recapped the schedule of data presentations for the Company’s lead compounds, umbralisib (TGR-1202), the Company’s once-daily PI3K delta inhibitor, and ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, at the upcoming 60thAmerican Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting and exposition, being held December 1-4, 2018, at the San Diego Convention Center (Press release, TG Therapeutics, NOV 30, 2018, View Source [SID1234532245]).
Presentations at the ASH (Free ASH Whitepaper) 2018 meeting include the following:
Oral Presentation Details:
Title: Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation
Publication Number: 297
Oral Session: 642. CLL: Therapy, excluding Transplantation: Cellular Therapy and Immunomodulation in CLL
Session Date and Time: Sunday, December 2, 2018; 7:30 AM – 9:00 AM PT
Presentation Time: 8:00 AM PT
Location: Marriott Marquis San Diego Marina, Pacific Ballroom 20
Presenter: Anthony R. Mato, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
Poster Presentation Details:
Title: Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Abstract Number: 4197
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster III
Date and Time: Monday, December 3, 2018; 6:00 PM – 8:00 PM PT
Location: San Diego Convention Center, Hall GH
Presenter: Matthew A. Lunning, DO, University of Nebraska Medical Center, Omaha, NE
The above referenced abstracts are available online and can be accessed on the ASH (Free ASH Whitepaper) meeting website at www.hematology.org. Following each presentation, the data presented will be available on the Publications page of the Company’s website at View Source
TG THERAPEUTICS INVESTOR & ANALYST EVENT
TG Therapeutics will also host a reception on Sunday, December 2, 2018 beginning at 7:30 PM PT with featured presentations beginning promptly at 8:00 PM PT. The event will take place in the Presidio A/B room, at the Marriott Gaslamp in San Diego, California. The event will be webcast live and will be available on the Events page, located within the Investors & Media section of the Company’s website at View Source, as well as archived for future review. This event will also be broadcast via conference call. To access the conference line, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), and reference Conference Title: TG TherapeuticsDecember 2018 Investor & Analyst Event.
On November 30, 2018 Forbius, a clinical-stage company developing biologics for the treatment of cancer and fibrosis, reported that its collaborators at the Icahn School of Medicine at Mount Sinai will present a poster tomorrow, Dec. 1, featuring AVID200, at the 60th ASH (Free ASH Whitepaper) Annual Meeting (Press release, Forbius, NOV 30, 2018, View Source [SID1234531778]).
Previous studies have shown that hyperactive TGF-beta signaling is a fundamental defect driving bone marrow fibrosis (Chagraoui et al., Blood, 2002). This presentation highlights the ability of AVID200 to shut down TGF-beta signaling, which decreases proliferation of mesenchymal stem cells and their collagen production. Importantly, when cells from myelofibrosis patients were treated with AVID200, this promoted proliferation of normal hematopoietic progenitors, while decreasing the proportion of myelofibrosis malignant progenitor cells.
AVID200 is uniquely positioned to be an effective treatment of MF because of isoform selectivity. TGF-beta 2 has been shown to be a positive promoter of hematopoiesis as well as normal cardiac function, whereas TGF-beta 1 and 3 promote fibrosis and myeloproliferation. AVID200 was therefore designed to selectively neutralize TGF-beta 1 & 3 for optimal efficacy and safety.
A Phase 1 trial evaluating AVID200 in patients with myelofibrosis is planned for early 2019.
The poster, entitled AVID200, a Potent Trap for TGF-β Ligands Inhibits TGF-β 1 Signaling in Human Myelofibrosis, will be presented by Lilian Varricchio, PhD, on Saturday, December 1st from 6:15 PM-8:15 PM PST in Hall GH of the San Diego Convention Center.
The abstract and full details for the poster presentation can be found on the ASH (Free ASH Whitepaper) website.
Forbius developed AVID200 to be a highly potent and isoform-selective TGF-β inhibitor. AVID200 neutralizes TGF-beta 1 and 3 with pM potency. These isoforms are known to be drivers of fibrosis and tumor immune resistance. In contrast, TGF-beta 2 is a positive regulator of hematopoiesis and normal cardiac function, therefore blockade of TGF-beta 2 is undesirable. The ability of AVID200 to selectively target TGF-beta 1 and 3 positions it to be an effective and well-tolerated therapeutic in fibrotic diseases and immune oncology.
On November 30, 2018 OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, reported that the Company will provide a corporate overview at the LD Micro 11th Annual Main Event Investor Conference, being held December 4-6, 2018 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA (Press release, BioTime, NOV 30, 2018, View Source;p=RssLanding&cat=news&id=2378868 [SID1234531771]).
OncoCyte Corporation Presentation Details:
Date: Tuesday, December 4
Time: 8:00am Pacific Time/11:00am Eastern Time
Location: Luxe Sunset Boulevard Hotel
On November 30, 2018 Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") reported that it will redeem $200 million aggregate principal amount of its outstanding 5.625% Senior Notes due 2021, CUSIP Nos. 91911KAD4, C94143AD3 (the "Notes") on Dec. 31, 2018 (Press release, Valeant, NOV 30, 2018, View Source [SID1234531770]). Bausch Health intends to use cash generated from operations to fund the aggregate redemption price for the Notes.
"Reducing our debt remains a priority for Bausch Health as we continue to transform the company, and due to strong recent operational cash flow, we are able to redeem these senior unsecured notes due in 2021," said Joseph C. Papa, chairman and CEO, Bausch Health.
Bausch Health issued today an irrevocable notice of redemption for the Notes, and a copy was issued to the record holders of such Notes. Payment of the redemption price and surrender of the Notes for redemption will be made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. The name and address of the paying agent are as follows: The Bank of New York Mellon Trust Company, N.A., c/o The Bank of New York Mellon; 111 Sanders Creek Parkway, East Syracuse, N.Y. 13057; Attn: Redemption Unit; Tel: 800-254-2826.